Page 31 - Jack Wang News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Winhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC-203 SHANGHAI and TAIPEI, Jan. 7, 2021 /PRNewswire/ — Hongkong Winhealth Pharma Group (Winhealth Pharma) and Taiwan TWi Biotechnology, Inc. (TWiB) announced strategic partnership granting Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 in mainland China, Hong Kong and Macao for indications including hereditary epidermolysis bullosa (EB), bullous pemphigoid and other skin diseases. The prevalence of EB in the United States is about 10.65 per million, equivalent to an estimated...

31 dicembre 2020 08:22 Fonte: Adnkronos #chimica-e-farmacia STOCKHOLM and HANGZHOU, China, Dec. 31, 2020 /PRNewswire/ -- Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti® (glycerol phenylbutyrate), in a territory covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand. Ravicti® is in Europe and North America indicated for treatment of urea cycle disorders (UCD), and under the announced partnership,...

Share this article Share this article STOCKHOLM and HANGZHOU, China, Dec. 30, 2020 /PRNewswire/ -- Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti ® (glycerol phenylbutyrate), in a territory covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand. Ravicti ® is in Europe and North America indicated for treatment of urea cycle disorders (UCD), and under the announced partnership, WinHealth is grante...

(1) STOCKHOLM and HANGZHOU, China, Dec. 31, 2020 /PRNewswire/ -- Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti (glycerol phenylbutyrate), in a territory covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand. Ravicti is in Europe and North America indicated for treatment of urea cycle disorders (UCD), and under the announced partnership, WinHealth is granted a license to register and commercializ...

MINISO Announces Unaudited Results for the 2021 First Fiscal Quarter Ended September 30, 2020 News provided by Share this article Share this article GUANGZHOU, China, Dec. 18, 2020 /PRNewswire/ -- MINISO Group Holding Limited (NYSE: MNSO) ("MINISO" or the "Company"), a fast-growing global value retailer offering a variety of design-led lifestyle products, today announced its unaudited financial results for the first fiscal quarter ended September 30, 2020. Financial Highlights for the 2021 First Fiscal Quarter Ended September 30, 2020 Revenue for the fiscal quarter ended September 30, 2020, ...